Breast Ultrasound Referrals Often Lack Important Info

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 11
Volume 15
Issue 11

There is a role forultrasound in breast cancer screening anddiagnosis, but many physicians do notseem to know what it is, according toAnnette Brown, MD, a radiologist in theMammography Division of Long IslandCollege Hospital in Brooklyn. A

NEW YORK--There is a role forultrasound in breast cancer screening anddiagnosis, but many physicians do notseem to know what it is, according toAnnette Brown, MD, a radiologist in theMammography Division of Long IslandCollege Hospital in Brooklyn. At the"Breast Cancer in Women of Color"meeting, Dr. Brown expressed her frustrationor "gripes" as she put it.

She called ultrasound the first line ofdefense for women under 40 who have amass, in order to spare them exams involvingradiation. "My gripe with anyphysician who is here," she said, "is whenyou send a patient for a sonogram, youcan't just say 'bilateral ultrasound' or 'ultrasoundright breast' and leave it at that.You have to say what you are looking for.Is there a mass in the breast? Where is it?Other than that, we're on a fishing expedition,and we may or may not find it."

Dr. Brown told ONI that she gets requestsfor bilateral ultrasounds every day."You have to waste your time callingthem. 'Excuse me, doctor, where is it?'Otherwise you are roaming around seeingwhat you bump into. If you cannotsay for sure that a mass is a simple cyst,then you have to do something about itand not say you didn't see it."

There are patients for whom such a"fishing expedition" makes sense, shesaid, eg, a young patient with densebreasts and a strong family history ofbreast cancer. "Because she has densebreasts, you are probably not going to seeanything on the mammogram. She deservesa second look with anything youhave. I think in a patient like that, youhave to go roaming around the breastand make sure there is nothing there.The problem, of course, is that such aggressivescreening can lead to more unnecessarybiopsies."

Women with dense breasts who havehad breast cancer also deserve screeningsonograms; even those without densebreasts deserve that second look, she said.'Of course, I explain the drawbacks tothe patient and the fact that we may notalways find an existing mass."

Although Dr. Brown feels ultrasoundis not ready for prime time as a breastscreening tool in the general population,still "it's a wonderful exam," she said. "Itgives us a lot of information and candistinguish between a cyst and a solidmass. However, since it is done with ahand-held transducer, if the technologistdoesn't put the transducer where theproblem is, we're not going to have apicture of it."

She further noted that ultrasound willnot find very small lesions in the breastor show lesions that have the same cysticproperties as the surrounding tissues ofthe breast. "The other problem is fattybreasts. I sometimes get a request for anultrasound, and find that the woman hasfatty breasts. Ultrasound doesn't like fat,"Dr. Brown said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content